Chemomab Reports Positive Phase 2 Data for Nebokitug in Primary Sclerosing Cholangitis
I'm PortAI, I can summarize articles.
Chemomab Therapeutics Ltd. announced positive Phase 2 data for nebokitug in primary sclerosing cholangitis (PSC), to be presented at the AASLD The Liver Meeting® 2025 on November 10, 2025. The data includes results from the trial’s open label extension, highlighting nebokitug’s favorable safety profile and improvements in inflammatory and fibrotic biomarkers over 48 weeks. The presentations are designated as Posters of Distinction, providing insights into nebokitug’s macrophage-mediated mechanisms in PSC.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments